마이크로 컴퓨팅 단층 촬영(Micro-CT) 이미징 방법을 사용하여 우주비행 후 글로벌 안구 구조 평가

Executive Industry Relevance

This study demonstrates the utility of micro-CT imaging for detecting structural changes in ocular tissues following exposure to spaceflight conditions, offering a non-destructive method to assess tissue-level responses to environmental stressors. The approach supports mechanistic de-risking in preclinical models by enabling quantitative evaluation of retinal, RPE, and choroid layer thickness, which are relevant to neuro-ocular syndrome research. These findings enhance predictive confidence in using rodent models to study environmental stress effects on global ocular structure, with implications for translational biomarker development and preclinical risk assessment.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses related to structural ocular changes induced by environmental stress.
• Operational Value: Supports biological de-risking through quantitative, reproducible measurement of tissue layer thickness in preclinical models.
• Predictive Value: Facilitates portfolio triage by providing measurable endpoints for assessing ocular safety in early discovery.

Screening & Assay Development

• Scientific Value: Delivers standardized, high-resolution imaging outputs suitable for assay standardization in ocular toxicity screening.
• Operational Value: Ensures reproducibility through non-destructive imaging and contrast-enhanced visualization of soft tissue structures.
• Scalability: Enables platform reuse across multiple ocular tissue types and experimental conditions.

Translational & Preclinical Research

• Scientific Value: Provides disease-relevant structural endpoints aligned with spaceflight-associated neuro-ocular syndrome (SANS) pathology.
• Operational Value: Supports translational continuity from discovery through preclinical validation via consistent imaging protocols.
• Risk-Adjusted Advancement: Informs go/no-go decisions by quantifying microstructural changes in ocular tissues under stress conditions.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from early target validation through preclinical evaluation, particularly for studies assessing environmental or physiological stressors on ocular structure.

• Discovery Biology: Supports hypothesis testing and pathway clarification by enabling precise measurement of retinal, RPE, and choroid layer alterations.
• Screening: Delivers assay readiness through standardized, quantitative imaging of ocular tissue cross-sections.
• Analytics: Generates linear and areal measurements that allow comparison between experimental and control conditions.
• Translational Research: Connects to preclinical continuity by providing structural biomarkers relevant to SANS-like phenotypes.
• Enterprise Reuse: Functions as a reusable imaging capability across multiple ocular disease models and stressor paradigms.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity in ocular structural responses.
• Operational Value: Enhances standardization and reproducibility through non-destructive, contrast-enhanced micro-CT workflows.
• Strategic Value: Improves capital efficiency by enabling early detection of ocular liability, reducing late-stage attrition risk.
• Portfolio Impact: Supports risk-adjusted prioritization through quantifiable, translatable ocular structural endpoints.

Implementation Considerations

• Requires expertise in micro-CT operation, image reconstruction, and tissue preparation for contrast agent staining.
• Dependent on access to high-resolution micro-CT instrumentation capable of micron-scale imaging.
• Necessitates cross-team standardization of fixation, dehydration, and staining protocols for reproducible results.
• Involves adaptation considerations when applying the method across different ocular models or species.
• Limited by the ex vivo nature of the technique, which precludes longitudinal in vivo tracking in the same subject.

Biopharma FAQs